mTORC1 and p53

References

• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274 - 93; http://dx.doi.org/10.1016/j.cell.2012.03.017; PMID: 22500797
   PubMed Web of Science ®Google Scholar
• Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10:307 - 18; http://dx.doi.org/10.1038/nrm2672; PMID: 19339977
   PubMed Web of Science ®Google Scholar
• Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007; 12:112 - 24; http://dx.doi.org/10.1016/j.drudis.2006.12.008; PMID: 17275731
   PubMed Web of Science ®Google Scholar
• Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene 2006; 25:6373 - 83; http://dx.doi.org/10.1038/sj.onc.1209889; PMID: 17041623
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5:578 - 81; http://dx.doi.org/10.1038/ncb999; PMID: 12771962
   PubMed Web of Science ®Google Scholar
• Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem 2009; 284:12783 - 91; http://dx.doi.org/10.1074/jbc.M809207200; PMID: 19299511
   PubMed Web of Science ®Google Scholar
• Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28:721 - 6; http://dx.doi.org/10.7164/antibiotics.28.721; PMID: 1102508
   PubMed Web of Science ®Google Scholar
• Koser PL, Eng WK, Bossard MJ, McLaughlin MM, Cafferkey R, Sathe GM, et al. The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding. Gene 1993; 129:159 - 65; http://dx.doi.org/10.1016/0378-1119(93)90264-4; PMID: 8325502
   PubMed Web of Science ®Google Scholar
• Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, et al, The Immunosuppression and Cancer Study Group. Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer 2012; 8049:00727 - 7; PMID: 23062667
   PubMedGoogle Scholar
• Hasty P. Rapamycin: the cure for all that ails. J Mol Cell Biol 2010; 2:17 - 9; http://dx.doi.org/10.1093/jmcb/mjp033; PMID: 19805415
   PubMed Web of Science ®Google Scholar
• Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14:5318 - 24; http://dx.doi.org/10.1158/1078-0432.CCR-07-5136; PMID: 18765522
   PubMed Web of Science ®Google Scholar
• Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010; 2:a000935; http://dx.doi.org/10.1101/cshperspect.a000935; PMID: 20679336
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413 - 31; http://dx.doi.org/10.1016/j.cell.2009.04.037; PMID: 19410540
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402 - 12; http://dx.doi.org/10.1038/nrm2395; PMID: 18431400
   PubMed Web of Science ®Google Scholar
• Meek DW. The p53 response to DNA damage. DNA Repair (Amst) 2004; 3:1049 - 56; http://dx.doi.org/10.1016/j.dnarep.2004.03.027; PMID: 15279792
   PubMed Web of Science ®Google Scholar
• Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155 - 68; http://dx.doi.org/10.1038/nrc1011; PMID: 12612651
   PubMed Web of Science ®Google Scholar
• Budanov AV, Lee JH, Karin M. Stressin’ Sestrins take an aging fight. EMBO Mol Med 2010; 2:388 - 400; http://dx.doi.org/10.1002/emmm.201000097; PMID: 20878915
   PubMed Web of Science ®Google Scholar
• Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206 - 8; http://dx.doi.org/10.1038/378206a0; PMID: 7477327
   PubMed Web of Science ®Google Scholar
• Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203 - 6; http://dx.doi.org/10.1038/378203a0; PMID: 7477326
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102:8204 - 9; http://dx.doi.org/10.1073/pnas.0502857102; PMID: 15928081
   PubMed Web of Science ®Google Scholar
• Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002; 10:995 - 1005; http://dx.doi.org/10.1016/S1097-2765(02)00706-2; PMID: 12453409
   PubMed Web of Science ®Google Scholar
• Horton LE, Bushell M, Barth-Baus D, Tilleray VJ, Clemens MJ, Hensold JO. p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene 2002; 21:5325 - 34; http://dx.doi.org/10.1038/sj.onc.1205662; PMID: 12149653
   PubMed Web of Science ®Google Scholar
• Fontoura BM, Atienza CA, Sorokina EA, Morimoto T, Carroll RB. Cytoplasmic p53 polypeptide is associated with ribosomes. Mol Cell Biol 1997; 17:3146 - 54; PMID: 9154813
   PubMed Web of Science ®Google Scholar
• Fontoura BM, Sorokina EA, David E, Carroll RB. p53 is covalently linked to 5.8S rRNA. Mol Cell Biol 1992; 12:5145 - 51; PMID: 1406686
   PubMed Web of Science ®Google Scholar
• Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8:317 - 25; http://dx.doi.org/10.1016/S1097-2765(01)00323-9; PMID: 11545734
   PubMed Web of Science ®Google Scholar
• Lai KP, Leong WF, Chau JF, Jia D, Zeng L, Liu H, et al. S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. EMBO J 2010; 29:2994 - 3006; http://dx.doi.org/10.1038/emboj.2010.166; PMID: 20657550
   PubMed Web of Science ®Google Scholar
• Lee CH, Inoki K, Karbowniczek M, Petroulakis E, Sonenberg N, Henske EP, et al. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J 2007; 26:4812 - 23; http://dx.doi.org/10.1038/sj.emboj.7601900; PMID: 17962806
   PubMed Web of Science ®Google Scholar
• Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003; 112:1223 - 33; PMID: 14561707
   PubMed Web of Science ®Google Scholar
• Habib SL, Yadav A, Mahimainathan L, Valente AJ. Regulation of PI 3-K, PTEN, p53, and mTOR in Malignant and Benign Tumors Deficient in Tuberin. Genes Cancer 2011; 2:1051 - 60; http://dx.doi.org/10.1177/1947601912445376; PMID: 22737271
   PubMedGoogle Scholar
• Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?. Aging (Albany NY) 2012; 4:450 - 5; PMID: 22869016
   PubMedGoogle Scholar
• Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012; 4:159 - 65; PMID: 22394614
   PubMedGoogle Scholar
• Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011; 192:547 - 56; http://dx.doi.org/10.1083/jcb.201009094; PMID: 21321098
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107:9660 - 4; http://dx.doi.org/10.1073/pnas.1002298107; PMID: 20457898
   PubMed Web of Science ®Google Scholar
• Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2010; 2:344 - 52; PMID: 20606252
   PubMedGoogle Scholar
• Yang K, Neale G, Green DR, He W, Chi H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol 2011; 12:888 - 97; http://dx.doi.org/10.1038/ni.2068; PMID: 21765414
   PubMed Web of Science ®Google Scholar
• Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149:1269 - 83; http://dx.doi.org/10.1016/j.cell.2012.04.026; PMID: 22682249
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Aging: ROS or TOR. Cell Cycle 2008; 7:3344 - 54; http://dx.doi.org/10.4161/cc.7.21.6965; PMID: 18971624
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY) 2011; 3:1078 - 91; PMID: 22156391
   PubMedGoogle Scholar
• Buitrago-Molina LE, Pothiraju D, Lamlé J, Marhenke S, Kossatz U, Breuhahn K, et al. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage. Hepatology 2009; 50:500 - 9; http://dx.doi.org/10.1002/hep.23014; PMID: 19642171
   PubMed Web of Science ®Google Scholar
• Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009; 119:99 - 106; http://dx.doi.org/10.1161/CIRCULATIONAHA.108.799700; PMID: 19103993
   PubMed Web of Science ®Google Scholar
• Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, et al. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. Biochem Pharmacol 2012; 83:480 - 8; http://dx.doi.org/10.1016/j.bcp.2011.11.022; PMID: 22142888
   PubMed Web of Science ®Google Scholar
• Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23:675 - 80; http://dx.doi.org/10.1101/gad.1772909; PMID: 19261747
   PubMed Web of Science ®Google Scholar
• Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 2011; 96:69 - 77; http://dx.doi.org/10.3324/haematol.2010.026997; PMID: 20952516
   PubMed Web of Science ®Google Scholar
• Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 2009; 69:4159 - 66; http://dx.doi.org/10.1158/0008-5472.CAN-08-4645; PMID: 19435901
   PubMed Web of Science ®Google Scholar
• Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis. Aging (Albany, NY Online) 2012; 4:728 - 35
   PubMedGoogle Scholar
• Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice. Aging (Albany, NY Online) 2012; 4:719 - 27
   Google Scholar
• Coppé JP, Rodier F, Patil CK, Freund A, Desprez PY, Campisi J. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem 2011; 286:36396 - 403; http://dx.doi.org/10.1074/jbc.M111.257071; PMID: 21880712
   PubMed Web of Science ®Google Scholar
• Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011; 479:232 - 6; http://dx.doi.org/10.1038/nature10600; PMID: 22048312
   PubMed Web of Science ®Google Scholar
• Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993; 8:2457 - 67; PMID: 8103211
   PubMed Web of Science ®Google Scholar
• García-Cao I, García-Cao M, Martín-Caballero J, Criado LM, Klatt P, Flores JM, et al. “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002; 21:6225 - 35; http://dx.doi.org/10.1093/emboj/cdf595; PMID: 12426394
   PubMed Web of Science ®Google Scholar
• Mendrysa SM, O’Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 2006; 20:16 - 21; http://dx.doi.org/10.1101/gad.1378506; PMID: 16391230
   PubMed Web of Science ®Google Scholar
• Matheu A, Pantoja C, Efeyan A, Criado LM, Martín-Caballero J, Flores JM, et al. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev 2004; 18:2736 - 46; http://dx.doi.org/10.1101/gad.310304; PMID: 15520276
   PubMed Web of Science ®Google Scholar
• Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002; 415:45 - 53; http://dx.doi.org/10.1038/415045a; PMID: 11780111
   PubMed Web of Science ®Google Scholar
• Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004; 18:306 - 19; http://dx.doi.org/10.1101/gad.1162404; PMID: 14871929
   PubMed Web of Science ®Google Scholar
• Moore L, Lu X, Ghebranious N, Tyner S, Donehower LA. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev 2007; 128:717 - 30; http://dx.doi.org/10.1016/j.mad.2007.10.011; PMID: 18061646
   PubMed Web of Science ®Google Scholar
• Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19:2122 - 37; http://dx.doi.org/10.1101/gad.1339905; PMID: 16131611
   PubMed Web of Science ®Google Scholar
• Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326:140 - 4; http://dx.doi.org/10.1126/science.1177221; PMID: 19797661
   PubMed Web of Science ®Google Scholar
• Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460:392 - 5; PMID: 19587680
   PubMed Web of Science ®Google Scholar
• Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66:191 - 201; http://dx.doi.org/10.1093/gerona/glq178; PMID: 20974732
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011; 10:4230 - 6; http://dx.doi.org/10.4161/cc.10.24.18486; PMID: 22107964
   PubMed Web of Science ®Google Scholar
• Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010; 11:453 - 65; http://dx.doi.org/10.1016/j.cmet.2010.05.001; PMID: 20519118
   PubMed Web of Science ®Google Scholar
• Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB, et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 2012; 223:102 - 13; http://dx.doi.org/10.1016/j.neuroscience.2012.06.054; PMID: 22750207
   PubMed Web of Science ®Google Scholar
• Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, et al. Rapamycin slows aging in mice. Aging Cell 2012; 11:675 - 82; http://dx.doi.org/10.1111/j.1474-9726.2012.00832.x; PMID: 22587563
   PubMed Web of Science ®Google Scholar
• Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med 2012; 4:ra103; http://dx.doi.org/10.1126/scitranslmed.3003802; PMID: 22837538
   PubMed Web of Science ®Google Scholar
• Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2012; 109:16666 - 71; http://dx.doi.org/10.1073/pnas.1202529109; PMID: 23012407
   PubMed Web of Science ®Google Scholar
• Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311:1621 - 3; http://dx.doi.org/10.1126/science.1124875; PMID: 16484451
   PubMed Web of Science ®Google Scholar